Maintenance immunotherapy after chemo for biliary tract cancer
Part of Cancer, Digestive system clinical trials.
This trial is for people with advanced biliary tract cancer who have already completed at least 8 cycles of a specific immunotherapy-chemo combination and are now moving to a maintenance phase with just the immunotherapy. It tests whether continuing a different immunotherapy alone can help keep the cancer from coming back longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have had at least 8 cycles of a specific type of chemotherapy (durvalumab or pembrolizumab plus gemcitabine and cisplatin) and now be continuing on just the immunotherapy drug.
- Your cancer must not have grown during that initial treatment.
- You must be 20 years old or older.
- You should be in fairly good health, able to do daily activities (ECOG 0 or 1), with adequate blood counts, kidney and liver function.
- You cannot have had another cancer in the last 3 years (except for some skin cancers or early-stage cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding another drug (lenvatinib or chemotherapy) to the immunotherapy drug pembrolizumab works better than pembrolizumab alone for advanced bile duct or gallbladder cancer that has not been treated before. It aims to find a more effective first treatment option.
This trial tests a combination of two drugs, zanzalintinib and durvalumab, as a maintenance treatment for people with advanced liver cancer (hepatocellular cancer) that has not gotten worse after initial treatment with tremelimumab and durvalumab. The goal is to see if this combination can help keep the cancer from growing.
This Phase 3 study tests whether a combination of lenvatinib, an immunotherapy medicine (tislelizumab), and chemotherapy (gemcitabine plus cisplatin) works better for advanced bile duct cancer that cannot be fully removed by surgery. It may help people live longer or control the cancer for longer.
This trial tests giving durvalumab (an immunotherapy drug) together with chemotherapy before surgery for bile duct or gallbladder cancer. The goal is to see if this combination shrinks tumors and improves outcomes for patients whose cancer is considered high-risk but still removable.
This trial tests two immunotherapy drugs (rilvegostomig or durvalumab) combined with standard chemotherapy for people with bile duct or gallbladder cancer that has spread or cannot be removed. It aims to see if these combinations work better than chemo alone.
This trial tests a new immunotherapy drug combined with standard chemotherapy as a first treatment for advanced bile duct or gallbladder cancer. It may help your immune system fight the cancer while chemotherapy attacks the tumor directly.
Hear when a new Biliary Tract Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.